Merck opens latest 2,700 square metre commercial facility in France

Merck opens their latest commercial manufacturing facility in Martillac, France, boasting rapid development and commercialisation of drug products with streamlined processes and state-of-the-art technology.

With two 2000-litre bioreactors in one manufacturing facility, the new site will deliver high levels of efficiency with the ability to rapidly pivot from 200 to 2000 litres of drug substance. Merck clients will be able to accelerate the commercialisation process of their products with the elimination of tech transfer and scale-up requirements between the clinical and commercial stages. Characterisation and safety testing integrated into differentiated CTDMO services will further streamline the development and commercialisation of drug products for Merck customers. All services will fall under the Millipore CTDMO Services offerings ranging from preclinical to commercial phases for therapeutic modalities including mAbs, highly potent active pharmaceutical ingredients, antibody–drug conjugates, viral vector therapies, mRNA, and lipid nanoparticle formulation.  

Head of Life Science Services, Life Science business sector at Merck Dirk Lange commented: “Our clients are pioneering modern medicine and managing multiple partners, supply chain needs and complex priorities, and are turning to Merck to help them navigate the complexity and provide flexibility and scale... With this facility and our global Millipore CTDMO Services network, we offer truly differentiated services, including templates for drug development, manufacturing, and commercialisation to accelerate molecules to market with one experienced partner.” 

Source: Merck Boosts Commercial Capacity in France as Part of New Millipore® CTDMO Services (sigmaaldrich.com)